β-Adrenergic Agonists

  • Clifton T. Furukawa
Part of the Current Clinical Practice book series (CCP)

Abstract

β-adrenergic agonists and especially β-2 adrenergic agonists are generally prescribed for all asthmatics as a backup medication to anti-inflammatory therapy or, in the case of exercise-induced asthma, as the primary drug. Technological advances have led to the development of increased β-2-specific adrenergic agonists of longer duration of action. The effectiveness of β-adrenergic agonists in treating asthma is indisputable. However, the very effectiveness of these drugs causes problems of overuse and consequent side effects raising such issues as whether other drugs or other parameters should be preferentially utilized.

Keywords

Adrenergic Agonist Dose Inhaler Asthma Death Injectable Route Adrenergic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. AAAAI Committee on Drugs, Position statement: safety and appropriate use of salmeterol in the treatment of asthma J. Allerg. Clin. Immunol. 1996; 98: 475–480.CrossRefGoogle Scholar
  2. Blauw GJ, Westendorp RGJ. Asthma deaths in New Zealand: whodunnit? Commentary. Lancet 1995; 345: 2,3.PubMedCrossRefGoogle Scholar
  3. Drugs for asthma. The Med Let 1995; 37: 1–4.Google Scholar
  4. Furukawa CT, Kemp JP, Simons FER, Tinkelman DG. The proper role of 132-adrenergic agaonists in the treatment of children with asthma. Pediatrics 1992; 90: 639–640.PubMedGoogle Scholar
  5. Gibson P, Henry D, Francis L, Chuickshank D, Dupen F, Higginbotham N, Henry R, Sutherland D, Association between availability of non-prescription beta 2 against inhalers and under treatment of asthma. Br Med J 1993; 306: 1514–1518.CrossRefGoogle Scholar
  6. McFadden ER. Perspectives in (32-agonist therapy: Vox clamantis in deserto vel lux tenebris? JAllergy Clin Immunol 1995; 95: 641–651.CrossRefGoogle Scholar
  7. Mullen M, Mullen B, Carey M. The association between 13-agonist use and death from asthma. JAMA 1993; 270: 1842–1845.PubMedCrossRefGoogle Scholar
  8. Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, Blais L, McNutt M, Buist AS, Spitzer WO. A cohort analysis of excess mortality in asthma and the use of inhaled (3-agonists. Am J Respir Crit Care Med 1994; 149: 604–610.PubMedGoogle Scholar
  9. Taylor DR, Sears MR. Regular beta-adrenergic atonists. Evidence, not reassurance, is what is needed. Chest 1994; 106: 552–559.CrossRefGoogle Scholar
  10. Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, Lake DC, Yates DM, Lucas MK, Li Q. Regular inhaled 13 agonist in asthma: effects on exacerbations and lung function. Thorax 1993; 48: 134–138.PubMedCrossRefGoogle Scholar
  11. Wahedna I, Wong CS, Wisniewski AFZ, Pavord AD, Tattersfield AE. Asthma control during and after cessation of regular beta-2 agonist treatment. Am Rev Respir Dis 1993; 148: 707–712.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Clifton T. Furukawa

There are no affiliations available

Personalised recommendations